

Prof. Başak OYAN ULUÇ

Personal Information

Office Phone: [+90 216 649 5172](tel:+902166495172)

Email: basak.uluc@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/basak.uluc>

Foreign Languages

English, C1 Advanced

Dissertations

Post Doctorate of Medicine, Diffüz büyük B hücreli lenfomalarda sağkalım ve prognostik faktörler, Hacettepe University, Sağlık Bilimleri Enstitüsü, Klinik Onkoloji A.B.D., 2004

Expertise In Medicine, Opere Evre I-III Meme Kanserlerinde Adjuvan Siklofosamid-Adriamisin-5-Florourasil (CAF) Kemoterapisi Sonuçları ve Prognozu Etkileyen Faktörler, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2001

Research Areas

Medicine, Oncology

Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydınlar University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2017 - Continues

Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2012 - 2016

Associate Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2006 - 2012

Assistant Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2006 - 2006

Professional Experience

Head of Department, Yeditepe University, Faculty Of Medicine, Department Of Basic Medical Sciences, 2008 - 2016

Courses

Epidemiology and etiology of cancer, Under Graduate, 2018 - 2019, 2019 - 2020

Epidemiology and etiology of cancer, Under Graduate, 2017 - 2018

Advising Theses

Oyan Uluç B., Sönmez Ö., Yüksek gradlı glial tümörlerde tanıda ve nükste PD-L1 ekspresyonu değişimi, Expertise In

Medicine, H.ŞEYMA(Student), 2016

Oyan Uluç B., Progrese glial tümörlerde mgmt (metil guanin-dna metil transferaz) metilasyonu ve idh (izositrat dehidrojenaz) mutasyonunda değişimin incelenmesi ve prognoza etkisinin araştırılması, Expertise In Medicine, M.AKİF(Student), 2014

Oyan Uluç B., Acute effects of Palonosetron on ECG parameters in cancer patients. , Post Doctorate of Medicine, C.AKOSMAN(Student), 2010

Oyan Uluç B., The prognostic relevance of response evaluation to chemotherapy using FDG-PET/CT in patients with advanced stage non-small-cell lung cancer, Post Doctorate of Medicine, Ç.ORDU(Student), 2010

Jury Memberships

Appointment Academic Staff, Appointment Academic Staff, Acıbadem Mehmet Ali Aydınlar Üniversitesi, October, 2019

Associate Professor Exam, Associate Professor Exam, Yeditepe Üniversitesi, May, 2015

Appointment Academic Staff, Appointment Academic Staff, Koç Üniversitesi, February, 2015

Appointment Academic Staff, Appointment Academic Staff, Mersin Üniversitesi, January, 2015

Associate Professor Exam, Associate Professor Exam, Hacettepe Üniversitesi, November, 2014

Appointment Academic Staff, Appointment Academic Staff, Selçuk Üniversitesi, May, 2014

Appointment Academic Staff, Appointment Academic Staff, Acıbadem Mehmet Ali Aydınlar Üniversitesi, October, 2013

Appointment Academic Staff, Appointment Academic Staff, Yeditepe Üniversitesi, June, 2013

Expertise In Medicine, Expertise In Medicine, Yeditepe Üniversitesi, October, 2012

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N., Paydas S., Demir G., Er O., Turhal N., Bavbek S., Eralp Y., Saip P., Güler N., et al.
BALKAN MEDICAL JOURNAL, vol.37, no.2, pp.104-107, 2020 (Journal Indexed in SCI)
- II. **The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study**
Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., Demirkazık A., Sak S. D. , Dilege S., Tanju S., Toker A., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)
- III. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M., Aksoy S., Aktas B., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (Journal Indexed in SCI)
- IV. **A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)**
Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacıoglu B., Oktay E., Erdem D., Arpacı E., Uluc B., Turhal S., et al.
JOURNAL OF BUON, vol.24, no.1, pp.242-248, 2019 (Journal Indexed in SCI)
- V. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
KILIÇKAP S., Ozturk A., Karadurmus N., Korkmaz T., YUMUK P. F. , Cicin I., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- VI. **Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.**

Oyan B., Sonmez Ö., Yazar A., Teomet M.

JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)

- VII. **Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
American journal of therapeutics, vol.23, 2016 (Journal Indexed in SCI Expanded)
- VIII. **Is It Time for Maintenance Chemotherapy for Advanced Gastric Adenocarcinoma?**
Eren O., Sönmez Ö., Oyan B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, pp.2067, 2016 (Journal Indexed in SCI Expanded)
- IX. **Bilateral synchronous adrenal metastasis of invasive ductal carcinoma treated with multimodality therapy including adrenalectomy and oophorectomy.**
Eren O., Ordu C., Selcuk N., Akosman C., Ozturk M., Özkan F., Gokce Ö., Oyan B.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.22, pp.157-60, 2016 (Journal Indexed in SCI Expanded)
- X. **May there be a role for hormonal manipulation for treatment of hormone receptor negative breast cancer?**
Onder E., Uysal S., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.1380, 2015 (Journal Indexed in SCI Expanded)
- XI. **Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study.**
Abali H., ÇELİK İ., Karaca B., Turna H., Sağlam E. K., Akman T., Oztop I., COŞKUN H. Ş., Turhal N. S., Sezer A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.4, pp.1137-41, 2015 (Journal Indexed in SCI)
- XII. **Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.**
Akosman C., Ordu C., Eroglu E., Oyan B.
American journal of therapeutics, vol.22, no.3, 2015 (Journal Indexed in SCI)
- XIII. **Revisiting post-gastrectomy anemia with a brief survey among a group of Turkish medical oncologists.**
Eren O., Sonmez Ö., Ozkan H., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.808-11, 2015 (Journal Indexed in SCI Expanded)
- XIV. **Voltage-gated sodium channel blockers can augment the efficacy of chemotherapeutics by their inhibitory effect on epithelial-mesenchymal transition.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
Medical hypotheses, vol.84, pp.11-3, 2015 (Journal Indexed in SCI Expanded)
- XV. **Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.**
Ordu C., Selcuk N., Akosman C., Eren O., Altunok E., Toklu T., Oyan B.
Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.321-6, 2015 (Journal Indexed in SCI Expanded)
- XVI. **Pituitary metastasis of colon adenocarcinoma: a rare occurrence.**
Ozturk M., Eren O., Sarikaya B., Aslan E., Oyan B.
Journal of gastrointestinal cancer, pp.85-7, 2014 (Journal Indexed in SCI Expanded)
- XVII. **Should we be more cautious about replacement of vitamin B12 in patients with cancer receiving cytotoxic chemotherapy?**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
Medical hypotheses, vol.83, pp.726-9, 2014 (Journal Indexed in SCI Expanded)
- XVIII. **Gastric metastasis in a patient with lobular breast carcinoma 6 years after diagnosis.**
Eren O., Ozturk M., Sonmez Ö., Aslan E., Ozkan F., Oyan B.
Journal of gastrointestinal cancer, vol.45, pp.504-5, 2014 (Journal Indexed in SCI Expanded)

- XIX. Voltage-gated sodium channel blockade for inhibition of EMT.**
Eren O., Oyan B.
Trends in pharmacological sciences, vol.35, pp.621, 2014 (Journal Indexed in SCI)
- XX. Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?**
Eren O., Ozturk M., Oyan B.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol.22, pp.2599-600, 2014 (Journal Indexed in SCI)
- XXI. Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.**
Rordorf T., Hassan A. A. , Azim H., Alexandru E., Er O., GÖKMEN E., Gural Z., Mardiak J., Minchev V., Peintinger F., et al.
Breast (Edinburgh, Scotland), vol.23, no.5, pp.511-25, 2014 (Journal Indexed in SCI)
- XXII. Does cetuximab cause small bowel perforation?**
Ozturk M., Eren O., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.865, 2014 (Journal Indexed in SCI)
- XXIII. Reply to the letter to the editor 'Are male gender and nonadenocarcinoma histology valid prognostic factors for breast cancer?' by Eren et al.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
ANNALS OF ONCOLOGY, vol.25, no.4, pp.911, 2014 (Journal Indexed in SCI)
- XXIV. Gallbladder perforation related to bevacizumab.**
Ozturk M., Kalayci M., Oyan B.
Clinics and research in hepatology and gastroenterology, vol.37, 2013 (Journal Indexed in SCI)
- XXV. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.**
Dent S., Oyan B., Honig A., Mano M., Howell S.
Cancer treatment reviews, vol.39, pp.622-31, 2013 (Journal Indexed in SCI)
- XXVI. Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.**
Ozturk M., Ozveren O., Cinar V., Erdik B., Oyan B.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol.24, pp.90-4, 2013 (Journal Indexed in SCI)
- XXVII. Why do targeted agents not work in the adjuvant setting in colon cancer?**
Oyan B.
Expert review of anticancer therapy, vol.12, pp.1337-45, 2012 (Journal Indexed in SCI)
- XXVIII. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.**
Oyan B.
Medical hypotheses, vol.77, pp.1028-30, 2011 (Journal Indexed in SCI)
- XXIX. The early metabolic effect of zoledronic acid on FDG-PET scans in patients with bone metastasis**
Selcuk N. A. , Uluc B., Akosman C., Ordu C., Toklu T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (Journal Indexed in SCI)
- XXX. Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment.**
Akosman C., Selcuk N. A. , Ordu C., Ercan S., Ekici I. D. , Oyan B.
Cancer imaging : the official publication of the International Cancer Imaging Society, vol.11, no.1, pp.52-5, 2011 (Journal Indexed in SCI)
- XXXI. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**
Ordu C., Selcuk N. A. , Akosman C., Oyan B.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXII. The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**
Ordu C., Selcuk N. A. , Akosman C., Oyan B.

- JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXIII. **The acute effects of palonosetron on ECG parameters in patients with cancer**
Akosman C., Ordu C., Oyan B.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXIV. **High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
Clinical transplantation, vol.23, pp.839-47, 2009 (Journal Indexed in SCI)
- XXXV. **Validation of FDG-PET/CT in evaluation of early remission in patients with refractory lymphoma after treatment with high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)**
Selcuk N. A. , Civi G., Toklu T., Oyan B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.36, 2009 (Journal Indexed in SCI)
- XXXVI. **The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.**
Yavas O., Yazici M., Eren O., Oyan B.
Swiss medical weekly, vol.137, pp.556-8, 2007 (Journal Indexed in SCI)
- XXXVII. **Hemorrhagic cystitis due to viral infection following hematopoietic stem cell transplantation**
Obek C., Kocagoz T., Aktas S., Yencilek F., Uluc B., Koc Y.
JOURNAL OF ENDOUROLOGY, vol.21, 2007 (Journal Indexed in SCI)
- XXXVIII. **Current medical treatment of pancreatic neuroendocrine tumors.**
Yalcin S., Oyan B., Bayraktar Y.
Hepato-gastroenterology, vol.54, pp.278-84, 2007 (Journal Indexed in SCI)
- XXXIX. **High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
Leukemia & lymphoma, vol.47, pp.1545-52, 2006 (Journal Indexed in SCI)
- XL. **Adding a single high-dose chemotherapy cycle to three cycles of standard salvage chemotherapy for relapsed germ-cell tumours does not improve clinical outcomes.**
Oyan B.
Cancer treatment reviews, vol.32, pp.45-9, 2006 (Journal Indexed in SCI)
- XLI. **Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy?**
Oyan B., Koc Y.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.17, pp.349-50, 2006 (Journal Indexed in SCI)
- XLII. **Prevalence and correlates of metabolic syndrome (MS) in older adults.**
Cankurtaran M., Halil M., Yavuz B., Dagli N., Oyan B., Ariogul S.
Archives of gerontology and geriatrics, vol.42, pp.35-45, 2006 (Journal Indexed in SCI)
- XLIII. **Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis.**
Oyan B., Koc Y., Emri S., Kansu E.
Medical oncology (Northwood, London, England), vol.23, pp.125-9, 2006 (Journal Indexed in SCI)
- XLIV. **Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol.11, pp.688-97, 2005 (Journal Indexed in SCI)
- XLV. **Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.**
Abali H., Oyan B., Guler N.

Chemotherapy, vol.51, pp.280-5, 2005 (Journal Indexed in SCI)

- XLVI. **IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.**
Abali H., Oyan B., Koc Y., Kars A., Barista I., Uner A., Turker A., Demirkazik F., Tekin F., Tekuzman G., et al.
American journal of clinical oncology, vol.28, pp.264-9, 2005 (Journal Indexed in SCI)
- XLVII. **Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.**
Oyan B., Koc Y., Kansu E.
International journal of hematology, vol.81, pp.155-8, 2005 (Journal Indexed in SCI)
- XLVIII. **A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.**
Koc Y., Oyan B., Kars A., Tekuzman G., Canpinar H., Kansu E.
Hematological oncology, vol.22, pp.43-53, 2004 (Journal Indexed in SCI)
- XLIX. **Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?**
Oyan B., Altundag K., Ozisik Y.
American journal of clinical oncology, vol.27, pp.210-1, 2004 (Journal Indexed in SCI)
- L. **Thymic malignancy in a breast cancer patient--is there an association with anti-estrogenic effects of tamoxifen?**
Oyan B., Aksoy S., Yavas O., Kars A., Turker A., Barista I.
Acta oncologica (Stockholm, Sweden), vol.43, pp.115-6, 2004 (Journal Indexed in SCI)
- LI. **Idiopathic fibrosclerosis of bilateral orbits, bilateral ureters, thyroid: a case report and review of the literature.**
Cankurtaran M., Oyan B., Kiliçkap S., Yavuz B., Batman F.
International urology and nephrology, vol.36, pp.495-8, 2004 (Journal Indexed in SCI Expanded)
- LII. **Epithelioid sarcoma of vulva - A case report and review of the literature**
Altundag K., Dikbas O., Oyan B., Usubutun A., Turker A.
MEDICAL ONCOLOGY, vol.21, no.4, pp.367-372, 2004 (Journal Indexed in SCI)
- LIII. **Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)**
Oyan B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., YALÇIN Ş., Guler N., Koc Y., Kansu E.
ANNALS OF ONCOLOGY, vol.15, pp.153, 2004 (Journal Indexed in SCI)
- LIV. **Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer**
Oyan B., Engin H., Yalcin S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.177-179, 2002 (Journal Indexed in SCI)
- LV. **Breast cancer and splenic non-Hodgkin's lymphoma, a rare occurrence [1]**
Engin H., Baltali E., Oyan B., Göksel H., Demirel B.
Breast Journal, vol.8, no.6, pp.400-401, 2002 (Journal Indexed in SCI Expanded)

Articles Published in Other Journals

- I. **Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**
Sezer A., Cicin İ., Karadeniz Ç., Özkan G., Başaran G., Oyan B., Eralp Y., Güllüoğlu B., Turkish N.
Turkish Journal of Surgery, vol.36, no.2, pp.147-163, 2020 (Journal Indexed in ESCI)
- II. **An unusual cause of arthritis: Carcinoma metastases**
ÖZLER T., SÖNMEZ Ö., EREN O. Ö., DOĞAN EKİCİ A. İ., GÜVEN M., ÇAĞATAY U., OYAN ULUÇ B.
Yeditepe Medical Journal , 2014 (Other Refereed National Journals)
- III. **Successful allogeneic marrow transplantation from donors with hematologic malignancies**
Koç Y., Oyan B., Akhtar M. S., Schenkein D. P., Miller K. B.

Turkish Journal of Cancer, vol.34, no.3, pp.118-121, 2004 (Refereed Journals of Other Institutions)

- IV. **Hematopoietic stem cell transplantation in hematologic malignancies and solid tumors: Hacettepe University Institute of Oncology experience**
Oyan B., Koç Y., Kars A., Türker A., Akyüz C., Güç D., Üner A., Ruacan Ş., Yiğitbaş E., Canpinar H., et al.
Turkish Journal of Cancer, vol.33, no.1, pp.27-39, 2003 (Refereed Journals of Other Institutions)
- V. **The prognostic factors for local disease free survival and distant disease free survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamide-adriamycin-5-fluorouracil (CAF) chemotherapy** Adjuvan siklofosfamid-adriamisil-5-florourasil (CAF) kemoterapisi alan opere evre I-III meme kanserli hastalarda lokal nüksüz ve uzak nüksüz sağkalimi etkileyen prognostik faktörler
Oyan B., Güler N., Tekuzman G., Kars A., Türker A., Altundağ M. K., Özişik Y., Baltalı E., Çelik I., Hamaloğlu E., et al.
THOD - Turk Hematoloji-Onkoloji Dergisi, vol.12, no.3, pp.115-125, 2002 (Refereed Journals of Other Institutions)
- VI. **The prognostic predictors for disease free survival and overall survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamideadriamycin-5-fluorouracil (CAF) chemotherapy**
Oyan B., Güler N., Kars A., Türker A., Altundağ K., Özişik Y., Baltalı E., Çelik I., Barişta I., Güllü I., et al.
Turkish Journal of Cancer, vol.32, no.3, pp.92-104, 2002 (Refereed Journals of Other Institutions)

Refereed Congress / Symposium Publications in Proceedings

- I. **Risks and characteristics of early-onset colorectal cancer: A single center retrospective study**
Yazar A., Koç E. S., Tözün A. N., Kutsal N. E., Önder F. O., Aygün C., Oyan Uluç B.
Proceedings of the World Congress of Gastroenterology, İstanbul, Turkey, 21 - 24 September 2019, pp.383
- II. **OnkoTürk Kayıt Sistemi: Solid Organ Maligniteli Hastalarda Tedavi ve İzlem Tercihlerinin Belirlenmesine Yönelik Kayıt Çalışması Ara Değerlendirme Sonuçları**
Alan Ö., Yumuk P. F., Dane F., Akgül Babacan N., Coşkun H. Ş., Sezgin Göksu S., Çelik İ., Oyan Uluç B., Yücel İ.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.292
- III. **Correlation of proliferation index markers (Ki-76 and PHH3) with breast MRI apparent diffusion coefficient values**
Ekemen S., Özcan A., Aksoy Özcan Ü., Ulus S., Oyan Uluç B.
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5
- IV. **Testing machine learning algorithms' performance for non-invasively identifying breast cancer molecular subtypes using BI-RADS evaluations**
Özcan İ. A., Aksoy Özcan Ü., Ekemen S., Ulus S., Oyan Uluç B.
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5
- V. **Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results**
Esin E., Oksuzoglu O. B. C., Bilici A., Cicin I., Aksoy S., Alacacioglu A., Kaplan M. A., Cabuk D., Sumbul A. T., Paydas S., et al.
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.104-105
- VI. **Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival**
Oyan B., Eren S., Sonmez O., Ozkan F., Yaltirak K., Ture U.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- VII. **Immunotherapy related cardiomyopathy.**
Sonmez Ö., Sever O. N., Oyan B., Demir O. G.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35
- VIII. **PD-L1 expression of high grade glial tumors at diagnosis and change of expression status at recurrence.**
Oyan B., Eren S., Sonmez Ö., Ozkan F., Yaltirak K., Ture U.
53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06

June 2017, vol.35

- IX. **Primary peritoneal hepatoid adenocarcinoma: Response to platin based chemotherapy.**
Oyan B., Sonmez Ö., Eren O. O. , Ozkan F., Ozgen A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- X. **The change in the status of MGMT methylation and IDH mutation in initial and recurrent glial tumors and its relation with prognosis.**
Oyan B., Ozturk M. A. , Ozkan F., Eren O. O. , Sonmez Ö.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XI. **Capecitabine maintenance after first-line induction chemotherapy with docetaxel cisplatin, and fluorouracil in patients with advanced gastric cancer**
Oyan B., Eren O. O. , Sonmez Ö.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XII. **Gallbladder perforation related to bevacizumab in a patient with lung adenocarcinoma.**
Oyan B., Ozturk M. A. , Kalayci M.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XIII. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**
Ozturk M., Ozaydin S., Oyan B., Ozbalak M., Arpacı F., Paydas S., Ataerğın S., Ferhanoglu B., Kocak N., Gurkan E., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XIV. **Hematopoietic stem cell transplantation for hematological diseases at yeditepe university hospital**
Yirmibescik S., Senkal V., Kalayci G., Aktas S., Aydin D., Sonmezoglu M., Kocagoz S., Oyan B.
Tandem BMT Meeting 2007, Colorado, United States Of America, 8 - 12 February 2007, vol.13, pp.94
- XV. **Nephrologic complications in stem cell transplantation**
Yakupoglu Ü., Uluc B., Koc Y.
44th ERA-EDTA Congress, Barcelona, Spain, 22 - 24 June 2007, vol.22, pp.56-57
- XVI. **Tropisetron does not induce arrhythmia in chemo-naive otherwise healthy cancer patients.**
Abali H., Abali G., Oksuzoglu B., Bakar M., Budakoglu B., Oyan B., Aytemur K., Zengin N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XVII. **High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL**
Oyan B., Koc Y., Ozdemir E., Kansu E.
31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35
- XVIII. **Nonmyeloablative allogeneic stem cell transplantation: Hacettepe University Institute of Oncology Experience.**
Koc Y., Ozdemir E., Oyan B., Kansu E.
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104
- XIX. **High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)**
Oyan B., Koc Y., Ozdemir E., Kansu E.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104

- XX. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXI. **Granisetron plus alprazolam versus granisetron alone in the control of emesis in patients with operable breast cancer receiving anthracycline containing chemotherapy: A phase III trial.**
Abali H., Oyan B., Ozisik Y., Guler N.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXII. **Outcome of well differentiated thyroid cancer: Single institution results.**
Aksoy S., Abali H., Kilickap S., Yavas O., Oyan B., Elkiran E., Aras T., Ugurlu O., Guler N., Tekuzman G.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXIII. **Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.**
Oyan B., Koc Y., Kars A., Turker A., Tekuzman G., Kansu E.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102
- XXIV. **Primary papillary serous carcinoma of the peritoneum: A retrospective analysis of 13 cases**
Oyan Uluç B., Abali H., Güler N., Kars A., Barışta İ., Tekuzman G.
ASCO Annual Meeting, Illinois, United States Of America, 31 May - 03 June 2003, vol.22, pp.1962
- XXV. **IIVP salvage regimen induces high response rates in patients with relapsed FED or NHL prior to autologous HSCT.**
Abali H., Koc Y., Oyan B., Tekin F., Tekuzman G., Kansu E.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100
- XXVI. **Successful salvage with high-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with Rituximab in patients with primary refractory mantle cell lymphoma presenting in leukemic phase.**
Oyan B., Koc Y., Tekin F., Kansu E.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100

Activities in Scientific Journals

Journal Of Oncological Sciences, Assistant Editor, 2016 - 2018

Memberships / Tasks in Scientific Organizations

ESMO, Principal Member, 2004 - Continues

ASCO, Principal Member, 2003 - Continues

Türk Tıbbi Onkoloji Derneği, Principal Member, 2001 - Continues

Türk Tıbbi Onkoloji Derneği (TTOD), Secretary General, 2014 - 2016

Scientific Refereeing

Project Supported by Higher Education Institutions, BAP Research Project, Istanbul University, Turkey, December 2020
European Journal Of Breast Health, Other Indexed Journal, June 2020
European Journal of Breast Health, Other Indexed Journal, April 2020
European Journal of Breast Health, Other Indexed Journal, December 2019
European Journal of Breast Health, Other Indexed Journal, October 2019
European Journal Of Breast Health, Other Indexed Journal, September 2019
European Journal Of Breast Health, Other Indexed Journal, May 2019
European Journal Of Breast Health, Other Indexed Journal, June 2017

Tasks In Event Organizations

Uras C., Güllüoğlu M. B. , Taşkın F., İçten S. G. , Arıbal M. E. , Çelik L., Beşe F. N. , Arıkan A. E. , Oyan Uluç B., Karanlık H., et al., Breastanbul 2020 4. Breast Cancer Conference , Scientific Congress, İstanbul, Turkey, Ekim 2020
Oyan Uluç B., SÖNMEZ Ö., Türk Tıbbi Onkoloji Deneği Meme Tümörleri Kursu, Scientific Congress, İstanbul, Turkey, Şubat 2020
Oyan Uluç B., 13. Meme kanserinde 2020 Güncel Tedavi Yaklaşımları Sempozyumu, Scientific Congress, Ankara, Turkey, Şubat 2020
Arıbal M. E. , OYAN ULUÇ B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, Ocak 2020
Oyan Uluç B., 6th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, Antalya, Turkey, Aralık 2019
Oyan Uluç B., 12. 1. İmmuno-Onkoloji okulu, Scientific Congress, İstanbul, Turkey, Nisan 2019
Arıbal M. E. , Oyan Uluç B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, Ocak 2019
Oyan Uluç B., BREASTANBUL 3rd Breast Cancer Conference, Scientific Congress, İstanbul, Turkey, Ekim 2018
Oyan Uluç B., 5th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, İstanbul, Turkey, Kasım 2017

Edit Congress and Symposium Activities

WebTARGED: İmmunoterapi ve Covid-19, Invited Speaker, İstanbul, Turkey, 2020
Onkoloji Okulum-Covid Platformu, Invited Speaker, İstanbul, Turkey, 2020
Onkoloji Okulum-Covid Platformu, Panelists, İstanbul, Turkey, 2020
Management of Cancer patients in the era of Covid-19 pandemic webinar , Invited Speaker, İstanbul, Turkey, 2020
ONCOvid-19, Invited Speaker, İstanbul, Turkey, 2020
Anaplastik Lenfoma Kinaz pozitif küçük hücreli dışı akciğer kanseri tedavisinde kilit konulara çok yönlü yaklaşım, Invited Speaker, İstanbul, Turkey, 2020
VII. Nadir Tümörler Sempozyumu, Invited Speaker, İzmir, Turkey, 2020
Türk Tıbbi Onkoloji Derneği (TTOD)-Meme Tümörleri kursu, Invited Speaker, İstanbul, Turkey, 2020
TTOD-Meme Tümörleri kursu, Moderator, İstanbul, Turkey, 2020
AKAD 2020: Ulusal Akciğer kanserleri Kongresi, Invited Speaker, Antalya, Turkey, 2020
3. Gençlerle Onkolojiye Bakış Kongresi, Invited Speaker, Antalya, Turkey, 2020
Meme kanserinde 2020 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, Ankara, Turkey, 2020
7th Lung Cancer Network «From the Bench to Bedside, Invited Speaker, Athens, Greece, 2020
Meme kanserinde yeni yaklaşımlar eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2020
Rektum kanseri tedavisinde konsensus toplantısı: İstanbul deklarasyonu, Invited Speaker, İstanbul, Turkey, 2020
Marmara Anadolu Yakası Meme Hastalıkları Mezuniyet Sonrası Eğitim Toplantıları (MAYMET)- Meme kanserinde biyolojik tedavilerin gelişen yüzü: Hedefler ve araçlar, Invited Speaker, İstanbul, Turkey, 2020
9th International Gastrointestinal Cancer Conference, Session Moderator, İstanbul, Turkey, 2019

6th Congress of Mediterranean Multidisciplinary Oncology Forum (MMOF)/3rd International Congress on Oncological Sciences (ICON), Panelists, Antalya, Turkey, 2019

6th Congress of Mediterranean Multidisciplinary Oncology Forum (MMOF)/3rd International Congress on Oncological Sciences (ICON), Invited Speaker, Antalya, Turkey, 2019

Antalya Onkolojide iz bırakanlar zirvesi, Invited Speaker, Antalya, Turkey, 2019

Meme kanseri: Çalışmalar ışığında deneyim paylaşımı, Session Moderator, İstanbul, Turkey, 2019

Comprehensive Genomic Profiling İstanbul Preceptorship, Invited Speaker, İstanbul, Turkey, 2019

15. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2019

CRO ve sektör temsilcileri için İmmuno-onkoloji Okulu, Invited Speaker, İstanbul, Turkey, 2019

Xth Euroasian Hematology Oncology Congress (EHOC 2019), Invited Speaker, İstanbul, Turkey, 2019

Xth Euroasian Hematology Oncology Congress (EHOC 2019), Invited Speaker, İstanbul, Turkey, 2019

Kişiselleştirilmiş Tedavi Çağında Göğüs Cerrahları için Onkoloji: TAKD ve TGCD /akciğer Kanseri Çalışma Grubu) Ortak Toplantısı, Invited Speaker, İstanbul, Turkey, 2019

İstanbul Reconstructive Breast Cancer Surgery (IREBS) Workshop 2019: Level III reconstructive Breast Cancer Surgery Workshop, Panelists, İstanbul, Turkey, 2019

İstanbul Reconstructive Breast Cancer Surgery (IREBS) Workshop 2019: Level III reconstructive Breast Cancer Surgery Workshop, Panelists, İstanbul, Turkey, 2019

6. Karadeniz Onkoloji Günleri, Invited Speaker, Trabzon, Turkey, 2019

2. İmmuno-Onkoloji okulu, Invited Speaker, Ankara, Turkey, 2019

Best of ASCO İstanbul 2019, Invited Speaker, İstanbul, Turkey, 2019

Practical Recommendations in Immuno & Molecular Oncology (PRIMO) 2019, Invited Speaker, İstanbul, Turkey, 2019

Practical Recommendations in Immuno & Molecular Oncology (PRIMO) 2019, Session Moderator, İstanbul, Turkey, 2019

Tanıdan Tedaviye Akciğer Kanseri Sempozyumu, Session Moderator, Muğla, Turkey, 2019

1. İmmuno-Onkoloji okulu, Invited Speaker, İstanbul, Turkey, 2019

Innovative Treatments in Lung Cancer: Scientific-practical conference, Invited Speaker, Kyyiv, Ukraine, 2019

23. Ulusal Kanser Kongresi (UKK), Invited Speaker, Antalya, Turkey, 2019

2. Eskişehir Onkoloji Günleri, Panelists, Eskişehir, Turkey, 2019

Acıbadem Altunizade Hastanesi Kolon Kanseri Farkındalık Söyleşisi, Panelists, İstanbul, Turkey, 2019

Meme kanserinde yeni yaklaşımlar eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2019

Citations

Total Citations (WOS):306

h-index (WOS):10